Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06422689 · ClinicalTrials.gov registry record · Phase 4
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
A Phase 4 study of Asthma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 4
- Development phase
- 1,507
- Enrollment target
- 11
- Study locations
NCT06422689: Active Phase 4 study of Asthma, sponsored by AstraZeneca.
NCT06422689 is a Phase 4 study of Asthma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,507 participants, roughly in line with the 1,559-participant average among 374 other Asthma trials with a reported enrollment target. The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06422689, a Phase 4 study of Asthma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,507 participants
- Enrollment target
- 11
- Study locations
Study Summary
ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.
Primary Outcome
Annualized Severe Asthma exacerbation rate
Conditions Studied
Interventions
- DRUG Albuterol and budesonide inhalation aerosol
Study Locations (11)
California
- Research Site - North Hollywood
- Research Site - Walnut Creek
Michigan
- Research Site - Ann Arbor
- Research Site - Flint
North Carolina
- Research Site - Asheville
- Research Site - Greenville
Kentucky
- Research Site - Louisville
Massachusetts
- Research Site - Boston
Minnesota
- Research Site - Minneapolis
Pennsylvania
- Research Site - DuBois
Texas
- Research Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,507 participants |
| Start Date | 2024-05-10 |
| Est. Completion | 2026-04-29 |
| Phase | Phase 4 |
What the registry record for NCT06422689 still lists
NCT06422689 is an interventional study that assigns participants to a tested intervention. Its 1,507 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,559-participant average among 374 other Asthma trials with a reported enrollment target.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Albuterol and budesonide inhalation aerosol is the first listed.
NCT06422689 lists 11 locations in 8 states (California, Michigan, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06422689 about?
NCT06422689 is a clinical study titled "Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care". ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonid...
What is the current status of trial NCT06422689?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 1,507 participants. The study started on 2024-05-10. Estimated completion is 2026-04-29.
What conditions does trial NCT06422689 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06422689?
The interventions under investigation include: Albuterol and budesonide inhalation aerosol (DRUG).
Who is sponsoring clinical trial NCT06422689?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06422689 being conducted?
This trial has 11 study locations across California, Kentucky, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06422689's enrollment target sits among peer trials
1,507 26th of 374 higher than 349 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI